This has been demonstrated by a study carried out in China in which 80 patients with LN and 20 healthy controls were recruited by measuring baseline plasma levels of IL-17 and IL-23 by enzyme-linked immunosorbent assay (ELISA) technique, wherein the end 37 patients with active LN accepted immunosuppressive therapy with a 6-month follow-up. This evidence concerns the gene IL17A and lobular neoplasia.